Clinical Research Directory

Inclusion Criteria: * Diagnosed as relapsed/refractory B cell Non-Hodgkin Lymphoma through cytological or pathological tissue examination according to the WHO 2016 standards * Age ≥18 years old * Have already received treatment with Ranicabtagene Autoleucel Injection through commercial channels at a study center in China that has obtained the commercial certification by HRAIN Biotechnology Co., Ltd. * Voluntarily participate in this study and sign the informed consent form. For patients who do not have full capacity for civil conduct, informed consent must also be obtained from their legal guardians Exclusion Criteria: * Patients who previously received CAR-T cell therapy targeting CD19